Topical antimicrobials for burn wound infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 2, 2010, Pages 124-151

  Dai, Tianhong ^a,b   Huang, Ying Ying ^a,b,c   Sharma, Sulbha K ^a   Hashmi, Javad T ^a,b   Kurup, Divya B ^a   Hamblin, Michael R ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Animal models; Antimicrobial peptide; Bioluminescence imaging; Burn infection; Chitosan; Multi drug resistance; Nanocrystalline silver; Photodynamic therapy; Skin substitute

Indexed keywords

ACTICOAT 7; ANTIINFECTIVE AGENT; BACITRACIN; CADEXOMER IODINE; CECROPIN B; CERAGENIN DERIVATIVE; CERIUM NITRATE; CHITIN; CHITOSAN; CHLORHEXIDINE; DEFENSIN; DEMEGEL D2A21; DUODERM; HISTONE H1; IOCIDE; LIPOSOMAL IODINE; MAFENIDE; MAFENIDE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NEOSPORIN; NITROFURAL; NYSTATIN; OMNIDERM; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; POVIDONE IODINE; PROBIOTIC AGENT; PSEUDOMONIC ACID; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; REPITHEL; SILVER NITRATE; SULFADIAZINE SILVER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIOLUMINESCENCE; BURN INFECTION; CLINICAL TRIAL; DEACETYLATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MONOCYTE; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEPSIS; T LYMPHOCYTE; UPREGULATION; WOUND CARE; WOUND DRESSING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIMICROBIAL CATIONIC PEPTIDES; BURNS; CHITOSAN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; HUMANS; IODINE; MODELS, BIOLOGICAL; PATENTS AS TOPIC; PHOTOCHEMOTHERAPY; SILVER; SKIN, ARTIFICIAL; WOUND INFECTION;

EID: 77954073587     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110791233522     Document Type: Article

References (258)

1. Sharma BR, Harish D, Singh VP, Bangar S. Septicemia as a cause of death in burns: An autopsy study. Burns 2006; 32(5): 545-9
2. Monafo WW. Then and now: 50 years of burn treatment. Burns 1992; 18(Suppl 2): S7-10.
3. Malic CC, Karoo RO, Austin O, Phipps A. Resuscitation burn card-a useful tool for burn injury assessment. Burns 2007; 33(2): 195-9.
4. Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton T, Gali H, et al. Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol 2005; 12(10): 1127-35
5. Robins EV. Burn shock. Crit Care Nurs Clin North Am 1990; 2(2): 299-307.
6. Macintire DK, Bellhorn TL. Bacterial translocation: Clinical implications and prevention. Vet Clin North Am Small Anim Pract 2002; 32(5): 1165-78.
7. Ben Saida N, Ferjeni A, Benhadjtaher N, Monastiri K, Boukadida J. Clonality of clinical methicillin-resistant Staphylococcus epidermidis isolates in a neonatal intensive care unit. Pathol Biol (Paris)2006; 54(6): 337-42.
8. Daoud Z, Moubareck C, Hakime N, Doucet-Populaire F. Extended spectrum beta-lactamase producing Enterobacteriaceae in Lebanese ICU patients: Epidemiology and patterns of resistance. J Gen Appl Microbiol 2006; 52(3): 169-78.
9. Migliavacca R, Migliavacca A, Nucleo E, Ciaponi A, Spalla M, De Luca C, et al. Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy. New Microbiol 2007; 30(3): 362-6.
10. Joseph-Horne T, Hollomon DW. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett1997; 149(2): 141-9.
11. Perlin DS. Antifungal drug resistance: Do molecular methods provide a way forward? Curr Opin Infect Dis 2009; 22(6): 568-73
12. Zhang YJ, Yu JJ, Zhang YN, Zhang X, Cheng CJ, Wang JX, et al. Effect of carbendazim resistance on trichothecene production and aggressiveness of Fusarium graminearum. Mol Plant Microbe Interact 2009; 22(9): 1143-50.
13. Avenot HF, Sellam A, Karaoglanidis G, Michailides TJ. Characterization of mutations in the iron-sulphur subunit of succinate dehydrogenase correlating with Boscalid resistance in Alternaria alternata from California pistachio. Phytopathology 2008; 98(6): 736-42.
14. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T. In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole. Rev Iberoam Micol 2005; 22(2): 105-9.
15. Khan ZU, Ahmad S, Brazda A, Chandy R. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: An emerging dimorphic pathogen with reduced susceptibility to posaconazole. J Clin Microbiol 2009; 47(4): 1244-8.
16. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006; 19(2): 403-34.
17. Greenhalgh DG, Saffle JR, Holmes JHt, Gamelli RL, Palmieri TL, Horton JW, et al. American Burn Association consensus con ference to define sepsis and infection in burns. J Burn Care Res 2007; 28(6): 776-90.
18. Sharma BR. Infection in patients with severe burns: Causes and prevention thereof. Infect Dis Clin North Am 2007; 21(3): 745-59, ix.
19. Neely AN, Brown RL, Clendening CE, Orloff MM, Gardner J, Greenhalgh DG. Proteolytic activity in human burn wounds. Wound Repair Regen 1997; 5(4): 302-9.
20. Samonte VA, Goto M, Ravindranath TM, Fazal N, Holloway VM, Goyal A, et al. Exacerbation of intestinal permeability in rats after a two-hit injury: Burn and Enterococcus faecalis infection. Crit Care Med 2004; 32(11): 2267-73.
21. Poole MD. Are we facing the end of the antibiotic era? Ear Nose Throat J 1993; 72(6): 433.
22. Davies J. Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 2006; 17(5): 287-90.
23. Dai T, Huang YY, Hamblin MR. Photodynamic therapy for localized infections-State of the art. Photodiagn Photodyn Ther 2009; 6(3-4): 170-88.
24. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009; 49(10): 1541-9.
25. Pawelchak, J.M., Freeman, F.M. Dressings, granules, and their use in treating wounds. US4538603 (1985).
26. Amani H, Dougherty WR, Blome-Eberwein S. Use of Transcyte and dermabrasion to treat burns reduces length of stay in burns of all size and etiology. Burns 2006; 32(7): 828-32.
27. Weiss J, Herman O, Rosenberg L, Shafir R. Use of meshed omiderm. Burns Incl Therm Inj 1988; 14(2): 161.
28. Hierlemann, H., Planck, H. Absorbable medical coating material and method for its manufacture. EP1181941 (2006).
29. Murray, D.G. Burn wound dressing material. US4659572 (1987).
30. Kiene S. Differential therapeutic indications for the useof Xenoderm and SYSpur-derm in burns and other skin defects. Zentralbl Chir 1981; 106(18): 1201-3.
31. Woodruff, E.A. Bio compatible and blood compatible materials and methods. US4820302 (1989).
32. Griffey, E.S., Livesey, S.A., Schiff, C.M., Boerboom, L.E. Particulate acellular tissue matrix. US7358284 (2008).
33. Heggers JP, Hawkins H, Edgar P, Villarreal C, Herndon DN. Treatment of infections in burns. In: Herndon DN, Ed. Total burn care. 3rd ed. London, England: Elsevier Health Sci 2002; 120-69
34. Johnson BA, Anker H, Meleney FL. Bacitracin: a new antibiotic produced by a member of the B. subtilis group. Science 1945; 102(2650): 376-7.
35. Palmieri TL, Greenhalgh DG. Topical treatment of pediatric patients with burns: a practical guide. Am J Clin Dermatol 2002; 3(8): 529-34.
36. Sinha R, Agarwal RK, Agarwal M. Povidone iodine plus Neosporin in superficial burns-a continuing study. Burns 1997; 23(7-8): 626-8.
37. Brown MR, Wood SM. Relation between cation and lipid content of cell walls of Pseudomonas aeruginosa, Proteus vulgaris and Klebsiella aerogenes and their sensitivity to polymyxin B and other antibacterial agents. J Pharm Pharmacol 1972; 24(3): 215-8
38. Munster AM. Treatment of invasive Enterobacter cloacae burn wound sepsis with topical nitrofurazone. J Trauma 1984; 24(6): 524.
39. Moyer CA, Brentano L, Gravens DL, Margraf HW, Monafo WW, Jr. Treatment of large human burns with 0.5 per cent silver nitrate solution. Arch Surg 1965; 90: 812-67.
40. Klasen, H.J. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26(2): 131-8
41. Jorgensen B, Price P, Andersen KE, Gottrup F, Bech-Thomsen N, Scanlon E, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: A randomised, controlled trial. Int Wound J 2005; 2(1): 64-73.
42. Monafo WW, Tandon SN, Ayvazian VH, Tuchschmidt J, Skinner AM, Deitz F. Cerium nitrate: A new topical antiseptic for extensive burns. Surgery 1976; 80(4): 465-73.
43. Fong J, Wood F. Nanocrystalline silver dressings in wound management: A review. Int J Nanomed 2006; 1(4): 441-9
44. Barnea Y, Weiss J, Gur E. A review of the applications of the hydrofiber dressing with silver (Aquacel Ag) in wound care. Ther Clin Risk Manage 2010; 6: 21-7.
45. Meaume S, Vallet D, Morere MN, Teot L. Evaluation of a silver releasing hydroalginate dressing in chronic wounds with signs of local infection. J Wound Care 2005; 14(9): 411-9.
46. Sawhney CP. Amniotic membrane as a biological dressing in the management of burns. Burns 1989; 15(5): 339-42.
47. Knutson, R.A. Wound-healing compositions containing povidone iodine. US4401651 (1983).
48. Johnson A. A combative healer with no ill-effect. Iodosorb in the treatment of infected wounds. Prof Nurse 1991; 7(1): 60, 2, 4
49. Reimer K, Fleischer W, Brogmann B, Schreier H, Burkhard P, Lanzendorfer A, et al. Povidone-iodine liposomes-an overview. Dermatology 1997; 195 (Suppl 2): 93-9.
50. Siegel, P., Bhatt, B. Process and composition for oral hygiene US20070292360 (2007).
51. Wong TW, Wang YY, Sheu HM, Chuang YC. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob Agents Chemother 2005; 49(3): 895-902
52. Dai T, Tegos GP, Lu Z, Huang L, Zhiyentayev T, Franklin MJ, et al. Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother 2009; 53(9): 3929-34.
53. Love, W., Brundish, D., Rhys-Williams, W., Feng, X.D., Pugin, B. Porphyrin derivatives and their use in photodynamic therapy. US7244841 (2007).
54. Hamblin, M.R., Wharton, T., Gali, H. Photosensitizers for targeted photodynamic therapy. WO2008136906 (2008).
55. Lambrechts SA, Demidova TN, Aalders MC, Hasan T, Hamblin MR. Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice. Photochem Photobiol Sci 2005; 4(7): 503-9
56. Orenstein A, Klein D, Kopolovic J, Winkler E, Malik Z, Keller N, et al. The use of porphyrins for eradication of Staphylococcus aureus in burn wound infections. FEMS Immunol Med Microbiol 1997; 19(4): 307-14.
57. Roncucci, G., Chiti, G., Dei, D., Cocchi, A., Fantetti, L., Mas cheroni, S. Phthalocyanine derivatives, process for their prepa ration, pharmaceutical compositions containing them and their use. US20090131392 (2009).
58. Hamblin, M.R., Foley, J.W. Antimicrobial photoinactivation using chalcogen analogs of benzo (A)phenoxazinium dyes. US20080015189 (2008).
59. Ribeiro MP, Espiga A, Silva D, Baptista P, Henriques J, Ferreira C, et al. Development of a new chitosan hydrogel for wound dressing. Wound Repair Regen 2009; 17(6): 817-24.
60. Sezer AD, Cevher E, Hatipoglu F, Ogurtan Z, Bas AL, Akbuga J. Preparation of fucoidan-chitosan hydrogel and its application as burn healing accelerator on rabbits. Biol Pharm Bull 2008; 31(12): 2326-33.
61. Dai T, Tegos GP, Burkatovskaya M, Castano AP, Hamblin MR. Chitosan acetate bandage as a topical antimicrobial dressing for infected burns. Antimicrob Agents Chemother 2009; 53(2): 393-400.
62. Ganz T, Lehrer RI. Defensins. Pharmacol Ther1995; 66(2): 191-205.
63. Chalekson CP, Neumeister MW, Jaynes J. Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plast Reconstr Surg 2002; 109(4): 1338-43.
64. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B, et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 2005; 12(20): 1494-502
65. Ren HT, Han CM, Zhang R, Xu ZJ, Meng ZQ, Weg HB, et al. The antibacterial effect of cecropin B on Pseudomonas aeruginosa infection of wounds in mice. Zhonghua Shao Shang Za Zhi 2006; 22(6): 445-7.
66. Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, Langer S, et al. Host defense peptides in wound healing. Mol Med 2008; 14(7-8): 528-37.
67. Epand RM, Epand RF, Savage PB. Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect 2008; 21(6): 307-11.
68. McManus AT, Denton CL, Mason AD, Jr. Topical chlorhexidine diphosphanilate (WP-973) in burn wound sepsis. Arch Surg 1984; 119(2): 206-11.
69. Miller LM, Loder JS, Hansbrough JF, Peterson HD, Monafo WW, Jordan MH. Patient tolerance study of topical chlorhexidine diphosphanilate: a new topical agent for burns. Burns 1990; 16(3): 217-20.
70. Selkon, J.B. Wound and ulcer treatment with super-oxidized water US7276255 (2007).
71. Hamouda T, Hayes MM, Cao Z, Tonda R, Johnson K, Wright DC, et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis 1999; 180(6): 1939-49.
72. Modak, S.M., Fox, C.L., Jr. Sulfadiazine silver-resistant Pseudo monas in burns. New topical agents. Arch Surg 1981; 116(7): 854-7.
73. Weller R, Price RJ, Ormerod AD, Benjamin N, Leifert C. Antimicrobial effect of acidified nitrite on dermatophyte fungi, Candida and bacterial skin pathogens. J Appl Microbiol 2001; 90(4): 648-52.
74. McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 2007; 51(6): 1934-8.
75. Ipaktchi K, Mattar A, Niederbichler AD, Hoesel LM, Vollmannshauser S, Hemmila MR, et al. Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model. Surgery 2007; 142(1): 86-93.
76. Peral MC, Martinez MA, Valdez JC. Bacteriotherapy with Lactobacillus plantarum in burns. Int Wound J 2009; 6(1): 73-81
77. Subrahmanyam M. Honey dressing versus boiled potato peel in the treatment of burns: A prospective randomized study. Burns 1996; 22(6): 491-3.
78. Edwards-Jones V, Buck R, Shawcross SG, Dawson MM, Dunn K. The effect of essential oils on methicillin-resistant Staphylococcus aureus using a dressing model. Burns 2004; 30(8): 772-7.
79. Zhang HQ, Yip TP, Hui I, Lai V, Wong A. Efficacy of moist exposed burn ointment on burns. J Burn Care Rehabil 2005; 26(3): 247-51.
80. Starley IF, Mohammed P, Schneider G, Bickler SW. The treatment of paediatric burns using topical papaya. Burns 1999; 25(7): 636-9
81. Stefanides MM Sr, Copeland CE, Kominos SD, Yee RB. In vitro penetration of topical antiseptics through eschar of burn patients. Ann Surg 1976; 183(4): 358-64.
82. Moghimi HR, Makhmalzadeh BS, Manafi A. Enhancement effect of terpenes on silver sulphadiazine permeation through third-degree burn eschar. Burns 2009; 35(8): 1165-70.
83. Manafi A, Hashemlou A, Momeni P, Moghimi HR. Enhancing drugs absorption through third-degree burn wound eschar. Burns 2008; 34(5): 698-702.
84. Lineaweaver W, Howard R, Soucy D, McMorris S, Freeman J, Crain C, et al. Topical antimicrobial toxicity. Arch Surg 1985; 120(3): 267-70.
85. Damour O, Hua SZ, Lasne F, Villain M, Rousselle P, Collombel C. Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. Burns 1992; 18(6): 479-85
86. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA. Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ Health Perspect 2010; 118(3): 407-13.
87. Supp AP, Neely AN, Supp DM, Warden GD, Boyce ST. Evaluation of cytotoxicity and antimicrobial activity of Acticoat Burn Dressing for management of microbial contamination in cultured skin substitutes grafted to athymic mice. J Burn Care Rehabil 2005; 26(3): 238-46.
88. Jacobsen F, Mohammadi-Tabrisi A, Hirsch T, Mittler D, Mygind PH, Sonksen CP, et al. Antimicrobial activity of the recombinant designer host defence peptide P-novispirin G10 in infected full thickness wounds of porcine skin. J Antimicrob Chemother 2007; 59(3): 493-8.
89. Soukos NS, Ximenez-Fyvie LA, Hamblin MR, Socransky SS, Hasan T. Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother 1998; 42(10): 2595-601.
90. Walker HL, Mason AD, Jr. A standard animal burn. J Trauma 1968; 8(6): 1049-51.
91. Jones WG, 2nd, Minei JP, Barber AE, Rayburn JL, Fahey TJ, 3rd, Shires GT, et al. Bacterial translocation and intestinal atrophy after thermal injury and burn wound sepsis. Ann Surg 1990; 211(4): 399-405.
92. Steinstraesser L, Klein RD, Aminlari A, Fan MH, Khilanani V, Remick DG, et al. Protegrin-1 enhances bacterial killing in thermally injured skin. Crit Care Med 2001; 29(7): 1431-7
93. Ulkur E, Oncul O, Karagoz H, Celikoz B, Cavuslu S. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and silver sulfadiazine 1% (Silverdin) for topical antibacterial effect in Pseudomonas aeruginosa-contaminated, full skin thickness burn wounds in rats. J Burn Care Rehabil 2005; 26(5): 430-3.
94. Stieritz DD, Holder IA. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Description of a burned mouse model. J Infect Dis 1975; 131(6): 688-91
95. Stevens EJ, Ryan CM, Friedberg JS, Barnhill RL, Yarmush ML, Tompkins RG. A quantitative model of invasive Pseudomonas infection in burn injury. J Burn Care Rehabil 1994; 15(3): 232-5
96. Bahar T, Bilezikci B, Maral T, Borman H. A modified partial thickness burn model in rats. Burns 2007; 33: S52-S3
97. Suzuki T, Hirayama T, Aihara K, Hirohata Y. Experimental studies of moderate temperature burns. Burns 1991; 17: 443-51
98. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol 1995; 18(4): 593-603.
99. Demidova TN, Gad F, Zahra T, Francis KP, Hamblin MR. Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. J Photochem Photobiol B 2005; 81: 15-25.
100. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 2005; 49(1): 380-7
101. Pham C, Greenwood J, Cleland H, Woodruff P, Maddern G. Bioengineered skin substitutes for the management of burns: A systematic review. Burns 2007; 33(8): 946-57.
102. Queen D, Evans JH, Gaylor JD, Courtney JM, Reid WH. Burn wound dressings-a review. Burns Incl Therm Inj 1987; 13(3): 218-28
103. Martin FT, O'Sullivan JB, Regan PJ, McCann J, Kelly JL. Hydrocolloid dressing in pediatric burns may decrease operative intervention rates. J Pediatr Surg 2010; 45(3): 600-5.
104. Eldad A, Tuchman I. The use of Omiderm as an interface for skin grafting. Burns 1991; 17(2): 155-8.
105. Schwarze H, Kuntscher M, Uhlig C, Hierlemann H, Prantl L, Ottomann C, et al. Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: Results of a clinical study. Ann Plast Surg 2008; 60(2): 181-5.
106. Mahnke PF, Rose E, Riedeberger J. A temporary synthetic skin subsitute: SYSpur-derm. Comparative histopathological exa mination. Zentralbl Chir 1980; 105(3): 145-53.
107. Barret JP, Dziewulski P, Ramzy PI, Wolf SE, Desai MH, Herndon DN. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg 2000; 105(1): 62-5
108. Hassan Z, Shah M. Punctate scarring from use of porous Biobrane. Burns 2006; 32(2): 258-60.
109. Naughton, G.K., Naughton, B.A. Three-dimensional cell and tissue culture system. US4963489 (1990).
110. Hosseini SN, Karimian A, Mousavinasab SN, Rahmanpour H, Yamini M, Zahmatkesh SH. Xenoderm versus 1% silver sulfadiazine in partial-thickness burns. Asian J Surg 2009; 32(4): 234-9.
111. Bell, E. Tissue-equivalent and method for preparation thereof. US4485096 (1984).
112. Allen-Hoffmann, B.L. Method and composition for skin grafts. US6964869 (2005).
113. Ceres, R.A., Brown, D.J., Lesnoy, D.C. Bilayered collagen construct. US6500464 (2002).
114. Murphy KD, Lee JO, Herndon DN. Current pharmacotherapy for the treatment of severe burns. Expert Opin Pharmacother 2003; 4(3): 369-84.
115. Altoparlak U, Erol S, Akcay MN, Celebi F, Kadanali A. The time related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 2004; 30(7): 660-4.
116. Elliott TS, Lambert PA. Antibacterial resistance in the intensive care unit: Mechanisms and management. Br Med Bull 1999; 55(1): 259-76.
117. Mcmanus, A. Anti microbial mafenide-phosphanilate compound, pharmaceutical compositions and method of use therefor. US200402 (1993).
118. Falcone PA, Harrison HN, Sowemimo GO, Reading GP. Mafenide acetate concentrations and bacteriostasis in experimental burn wounds treated with a three-layered laminated mafenide-saline dressing. Ann Plast Surg 1980; 5(4): 266-9.
119. Heggers JP, Robson MC, Herndon DN, Desai MH. The efficacy of nystatin combined with topical microbial agents in the treatment of burn wound sepsis. J Burn Care Rehabil 1989; 10(6): 508-11
120. Monafo WW, West MA. Current treatment recommendations for topical burn therapy. Drugs 1990; 40(3): 364-73.
121. Alvarez, O.M. Zinc bacitracin containing wound dressing patent. US5061689 (1991).
122. Rode H, de Wet PM, Millar AJ, Cywes S. Bactericidal efficacy of mupirocin in multi-antibiotic resistant Staphylococcus aureus burn wound infection. J Antimicrob Chemother 1988; 21(5): 589-95
123. Strock LL, Lee MM, Rutan RL, Desai MH, Robson MC, Herndon DN, et al. Topical bactroban (mupirocin): Efficacy in treating burn wounds infected with methicillin-resistant Staphylococci. J Burn Care Rehabil 1990; 11(5): 454-9.
124. Drogemoller, M.L., Linley, S.L. Composition comprising mupirocin and chlorhexidine. US6214866 (2001).
125. Embil JM, McLeod JA, Al-Barrak AM, Thompson GM, Aoki FY, Witwicki EJ, et al. An outbreak of methicillin resistant Staphylococcus aureus on a burn unit: Potential role of contaminated hydrotherapy equipment. Burns 2001; 27(7): 681-8
126. Meier PA, Carter CD, Wallace SE, Hollis RJ, Pfaller MA, Herwaldt LA. A prolonged outbreak of methicillin-resistant Staphylococcus aureus in the burn unit of a tertiary medical center. Infect Control Hosp Epidemiol 1996; 17(12): 798-802.
127. Hansbrough JF, Zapata-Sirvent RL, Cooper ML. Effects of topical antimicrobial agents on the human neutrophil respiratory burst. Arch Surg 1991; 126(5): 603-8.
128. Darouiche, R.O., Raad, I. Antimicrobial impregnated catheters and other medical implants. US5624704 (1999).
129. Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001; 61(3): 353-64.
130. Mousa HA. Fungal infection of burn wounds in patients with open and occlusive treatment methods. East Mediterr Health J 1999; 5(2): 333-6.
131. Lopez-Berestein, G., Mehta, R., Hopfer, R.L., Juliano, R.L. Liposome-incorporated nystatin. US4812312 (1989).
132. Kwon, G.S., Yoo, B.K. Nystatin formulation having reduced toxicity. US6413537 (2002).
133. Yapijakis C. Hippocrates of Kos, the father of clinical medicine, and Asclepiades of Bithynia, the father of molecular medicine. Review. In Vivo 2009; 23(4): 507-14.
134. Alexander JW. History of the medical use of silver. Surg Infect (Larchmt) 2009; 10(3): 289-92.
135. Borsuk DE, Gallant M, Richard D, Williams HB. Silver-coated nylon dressings for pediatric burn victims. Can J Plast Surg 2007; 15(1): 29-31.
136. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns 2007; 33(2): 139-48.
137. Warriner R, Burrell R. Infection and the chronic wound: A focus on silver. Adv Skin Wound Care 2005; 18 (Suppl 1): 2-12.
138. Poon VK, Burd A. In vitro cytotoxity of silver: Implication for clinical wound care. Burns 2004; 30(2): 140-7.
139. Kershaw, D., DeBoorder, B., Law, S.J. Antibacterial wound dressing. US20100015208 (2010).
140. Mason, A.D.J., Johnson, A.A.J., Ritchey, C.R. Protective gel composition for treating white phosphorus burn wounds US4391799 (1983).
141. Schmolka, I.R. Silver ion gel compositions. US4376764 (1983).
142. Neuwirth, R.S. Intrauterine chemical cauterizing method and composition. US2008895424 (2008).
143. Zanoni D, Isenberg SJ, Apt L. A comparison of silver nitrate with erythromycin for prophylaxis against ophthalmia neonatorum. Clin Pediatr (Phila) 1992; 31(5): 295-8.
144. Fox CL Jr., Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother 1974; 5(6): 582-8.
145. Lee CAR, Leem H, Lee J, Park KC. Reversal of silver sulfadiazine-impaired wound healing by epidermal growth factor. Biomaterials 2005; 26(22): 4670-6.
146. Rosenkranz HS, Coward JE, Wlodkowski TJ, Carr HS. Properties of silver sulfadiazine-resistant Enterobacter cloacae. Antimicrob Agents Chemother 1974; 5(2): 199-201.
147. Fox, C.L.J., Modak, S.M. Antibacterial composition comprising silver sulfadiazine and sodium piperacillin. US4535078 (1985)
148. Modak, S.M., Fox, C.L.J., Fox, P. Wound dressing comprising silver sulfadiazine incorporated in animal tissue. CA1219209 (1987).
149. Fox, C.L.J. Silver sulfadiazine used in the treatment of burns. US3761590 (1973).
150. Chen, J.R. Topical spray for burn treatment and anti-infection. US6551577 (2003).
151. Garner JP, Heppell PS. Cerium nitrate in the management of burns. Burns 2005; 31(5): 539-47.
152. Monafo, W.W. Water-soluble cerium (cerous) salts in burn therapy US4088754 (1978).
153. Gravante, G., Caruso, R., Sorge, R., Nicoli, F., Gentile, P., Cervelli, V. Nanocrystalline silver: A systematic review of randomized trials conducted on burned patients and an evidence based assessment of potential advantages over older silver formulations. Ann Plast Surg 2009; 63(2): 201-5.
154. Ma, R.H., Yu, Y.H. Nano-silver wound dressing. US7462753 (2008).
155. Holladay, R.J., Christensen, H., Moeller, W.D. Treatment of humans with colloidal silver composition. US7135195 (2006)
156. Gillis, S.H. Therapeutic treatments using the direct application of antimicrobial metal compositions. US20060083792 (2006)
157. Gillis, S.H. Therapeutic treatments using the direct application of antimicrobial metal compositions. US6989156 (2006)
158. Bell A, Hart J. Evaluation of two absorbent silver dressings in a porcine partial-thickness excisional wound model. J Wound Care 2007; 16(10): 445-8, 50-3.
159. Scherr, G.H. Silver alginate foam compositions. US0021832 (2003).
160. Kim, Y.S., Kim, J.Y. Methods for producing silver-bonded antimicrobial moist wound dressings and moist wound dressings produced by the methods. EP1993620 (2008).
161. Ma, R.H., Yu, Y.H. Nano-silver wound dressing. US7462753 (2008).
162. Mcknight, J.J., Guldalian, J.J. Laminated collagen film dressing. US3800792 (1974).
163. Lerat, Y.J., Poncelet, O.J. Dressing and antiseptic agent containing silver. US7323614 (2008).
164. Haberal M, Oner Z, Bayraktar U, Bilgin N. The use of silver nitrate-incorporated amniotic membrane as a temporary dressing. Burns Incl Therm Inj 1987; 13(2): 159-63.
165. Singh R, Kumar D, Kumar P, Chacharkar MP. Development and evaluation of silver-impregnated amniotic membrane as an antimicrobial burn dressing. J Burn Care Res 2008; 29(1): 64-72
166. Fox, C.L.J, Modak, S.M., Fox, P. Wound dressing comprising silver sulfadiazine incorporated in animal tissue. US4446124 (1984).
167. Capelli, C. Stabilized silver-ion amine complex compositions and methods. US6923990 (2005).
168. Leaper DJ, Durani P. Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products. Int Wound J 2008; 5(2): 361-8.
169. Durani P, Leaper D. Povidone-iodine: Use in hand disinfection, skin preparation and antiseptic irrigation. Int Wound J 2008; 5(3): 376-87.
170. Zamora JL. Iodine toxicity. Ann Thorac Surg 1986; 41(4): 462-3.
171. Capriotti, J.A., Liang, B., Samson, C.M., Stein, J., Weise, M. Device for in situ generation of povidone-iodine compositions. WO2009097123 (2009).
172. Beukelman CJ, van den Berg AJ, Hoekstra MJ, Uhl R, Reimer K, Mueller S. Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns 2008; 34(6): 845-55.
173. Muhlau, S., Fleischer, W. Dry liposomal PVP-iodine compositions. US2004234589 (2004).
174. Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed) 1985; 291(6491): 308-10.
175. Kota, S., Adibhatla, K.S., Venkaiah, C.N. Improved process for the preparation of cadexomer iodine. WO2008117300 (2008)
176. Larsen, N. Anti-infective iodine based compositions for otic and nasal use. US2006280809 (2006).
177. Scholtz, M.T. Liquid antiseptic compositions containing iodine and A sugar and/or sugar alcohol. WO2009088826 (2009).
178. Foret, C., Hemling, T.C. Iodine antimicrobial compositions con taining nonionic surfactants and halogen anions. US5916581 (1999).
179. Hamblin MR, Mroz P. Advances in Photodynamic Therapy: Basic, Translational and Clinical. Norwood, MA: Artech House 2008
180. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003; 23(5A): 3591-600.
181. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: Part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 2004; 1(4): 279-93.
182. Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004; 3(5): 436-50.
183. Phoenix DA, Harris F. Light activated compounds as antimicrobial agents - patently obvious? Recent Pat Antiinfect Drug Discov 2006; 1(2): 181-99.
184. Nifantiev, N.E., Gitter, B., Yashunsky, D.V. Anti-microbial photodynamic therapy. US2007016951 (2007).
185. Hasan, T., Hamblin, M.R., Soukos, N.S. Photosensitizer conjugates for pathogen targeting. US7268155 (2007).
186. Hamblin MR, O'Donnell DA, Murthy N, Rajagopalan K, Michaud N, Sherwood ME, et al. Polycationic photosensitizer conjugates: Effects of chain length and Gram classification on the photodynamic inactivation of bacteria. J Antimicrob Chemother 2002; 49(6): 941-51.
187. Tegos GP, Anbe M, Yang C, Demidova TN, Satti M, Mroz P, et al. Protease-stable polycationic photosensitizer conjugates between polyethyleneimine and chlorin(e6) for broad-spectrum antimicro bial photoinactivation. Antimicrob Agents Chemother 2006; 50(4): 1402-10.
188. Raghavendra M, Koregol A, Bhola S. Photodynamic therapy: A targeted therapy in periodontics. Aust Dent J 2009; 54 (Suppl 1): S102-9.
189. Hamblin, M.R., Tegos, G.P. Inactivation of Microorganisms with multidrug resistance inhibitors and phenothiaziniums. US20080166304 (2008).
190. Biel, M.A. Photodynamic therapy utilizing a solution of photo sensitizing compound and surfactant. US7229447 (2007).
191. Albrecht, V., Gitter, B. Antimicrobial photodynamic therapy compound and method of use. US20050049228 (2005).
192. Albrecht, V., Fahr, A., Scheglmann, D., Gräfe, S., Neuberger, W. Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy. US7354599 (2008).
193. Van Der Haas, H.N., Lugtenburg, J., Schuitmaker, J., De Jong, R.L. Method of preparing a porphyrin derivative, a porphyrin derivative, use of said porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative. US20090215851 (2009).
194. Smijs, G.M., Schuitmaker, J.J. Use of a porphyrin compound for the treatment of skin fungi. US20060258635 (2006).
195. Love, W., Brundish, D., Rhys-Williams, W., Feng, X.D., Pugin, B. Porphyrin derivatives and their use in photodynamic therapy. US7244841 (2007).
196. Rabea EI, Badawy ME, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules 2003; 4(6): 1457-65.
197. Sparkes, B.G., Murray, D.G. Chitosan based wound dressing materials. US4572906 (1986).
198. Yura, H., Saito, Y., Ishihara, M., Ono, K., Saeki, S. Functional chitosan derivative. US7125968 (2006).
199. Baker, S., Wiesmann, W.P. Methods and compositions for the prevention of and treatment of infections utilizing chitosan derivative compounds. US20100056474 (2010).
200. Scherr, G.H. Chitosan wound dressing. US20070237811 (2007).
201. Muzzarelli, R. Methyl pyrrolidinone chitosan, production process and uses thereof. US5378472 (1995).
202. Alsarra IA. Chitosan topical gel formulation in the management of burn wounds. Int J Biol Macromol 2009; 45(1): 16-21
203. Aoyagi S, Onishi H, Machida Y. Novel chitosan wound dressing loaded with minocycline for the treatment of severe burn wounds. Int J Pharm 2007; 330(1-2): 138-45.
204. Boucard N, Viton C, Agay D, Mari E, Roger T, Chancerelle Y, et al. The use of physical hydrogels of chitosan for skin regene ration following third-degree burns. Biomaterials 2007; 28(24): 3478-88.
205. Cardenas G, Anaya P, von Plessing C, Rojas C, Sepulveda J. Chitosan composite films. Biomedical applications. J Mater Sci Mater Med 2008; 19(6): 2397-405.
206. [206] Sezer AD, Hatipoglu F, Cevher E, Ogurtan Z, Bas AL, Akbuga J. Chitosan film containing fucoidan as a wound dressing for dermal burn healing: Preparation and in vitro/ in vivo evaluation. AAPS Pharm Sci Tech 2007; 8(2): Article 39.
207. Damour O, Gueugniaud PY, Berthin-Maghit M, Rousselle P, Berthod F, Sahuc F, et al. A dermal substrate made of collagen GAG-chitosan for deep burn coverage: First clinical uses. Clin Mater 1994; 15(4): 273-6.
208. Peh K, Khan T, Ch'ng H. Mechanical, bioadhesive strength and biological evaluations of chitosan films for wound dressing. J Pharm Pharm Sci 2000; 3(3): 303-11.
209. Mor A. Multifunctional host defense peptides: Antiparasitic activities. FEBS J 2009; 276(22): 6474-82.
210. Schittek B, Paulmann M, Senyurek I, Steffen H. The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets 2008; 8(3): 135-43
211. Selsted ME, Szklarek D, Lehrer RI. Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. Infect Immun 1984; 45(1): 150-4.
212. Lehrer RI, Szklarek D, Ganz T, Selsted ME. Correlation of binding of rabbit granulocyte peptides to Candida albicans with candidacidal activity. Infect Immun 1985; 49(1): 207-11
213. Lehrer RI, Daher K, Ganz T, Selsted ME. Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol 1985; 54(2): 467-72.
214. Pazgier M, Prahl A, Hoover DM, Lubkowski J. Studies of the biological properties of human beta-defensin 1. J Biol Chem 2007; 282(3): 1819-29.
215. Fulton C, Anderson GM, Zasloff M, Bull R, Quinn AG. Expression of natural peptide antibiotics in human skin. Lancet 1997; 350(9093): 1750-1.
216. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: A novel beta-defensin from human plasma. FEBS Lett 1995; 368(2): 331-5.
217. Zhao C, Wang I, Lehrer RI. Widespread expression of beta defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396(2-3): 319-22.
218. Bhat S, Milner S. Antimicrobial peptides in burns and wounds. Curr Protein Pept Sci 2007; 8(5): 506-20.
219. Strom, R.M., Brondsema, P.J. Periodic antimicrobial peptides. US7091185 (2006).
220. Strom, R.M., Brondsema, P.J. Periodic antimicrobial peptides. US20050187151 (2005).
221. Schwab U, Gilligan P, Jaynes J, Henke D. In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrob Agents Chemother 1999; 43(6): 1435-40.
222. Chalekson CP, Neumeister MW, Jaynes J. Treatment of infected wounds with the antimicrobial peptide D2A21. J Trauma 2003; 54(4): 770-4.
223. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: Perspectives in cancer epigenetics. Mol Cancer Ther 2008; 7(4): 740-8.
224. Rose FR, Bailey K, Keyte JW, Chan WC, Greenwood D, Mahida YR. Potential role of epithelial cell-derived histone H1 proteins in innate antimicrobial defense in the human gastrointestinal tract. Infect Immun 1998; 66(7): 3255-63.
225. Pohlmeyer K, Behnke B, Wick RZ, Mayer G. Recombinant production of human histone 1 subtypes and their use for therapeutic purposes. US20030078204 (2003).
226. Lai JS, Lee JH, Callaway JE. Cecropin polypetides with activity against Gram-positive and Gram-negative bacteria. US5166321 (1992).
227. Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Orlando F, D'Amato G, et al. Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock. Ann Surg 2004; 239(2): 251-6.
228. Horwitz, A., Lambert, L.H.J., Little, R.G. Anti-gram-positive bacterial methods and materials. US5578572 (1996).
229. Savage, P.B., Li, C. Steroid derived antibiotics. US6486148 (2002).
230. Savage, P.B., Li, C. Steroid derived antibiotics. US6767904 (2004).
231. Savage, P.B., Li, C. Steroid derived antibiotics. US7598234 (2009).
232. Dang, X., Zhang, W., Wang, Y., Zheng, X., Wang, J.X., Wang, L. Musca domestic pupae natural antimicrobial peptide products and preparation method and use thereof. CN101392020 (2009)
233. Beuerman, R.W., Liu, S., Li, J., Zhou, L., Verma, C.S., Tan, D. Multimeric forms of antimicrobial peptides. WO2009131548 (2009).
234. Liepke, C., Baxmann, S., Adermann, K. Novel antimicrobial bolisin peptides. US2009149391 (2009).
235. Oppenheim, F.G., Xu, T., Roberts, F.D., Spacciapoli, P., Friden, P.M. Anti-fungal and anti-bacterial histatin-based peptides. US5912230 (1999).
236. Hara, S. Peptide, antibacterial agent, peptide gene, recombinant DNA and method for preparing the peptide. US5646014 (1997)
237. Djurup, R., Flodgaard, H.J., Norris, K. Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin binding protein (Hbp) or human neutrophil elastase. WO2004016653 (2004).
238. Schmidtchen, A., Malmsten, M. Improved antimicrobial peptides KR0027213 (2009).
239. Krieger, T.J., Taylor, R., Erfle, D., Fraser, J.R., West, M.H., Mcnichol, P.J. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics. US6503881 (2009).
240. Drake, D., Marek, C.L. Chlorhexidine compositions. US20050191247 (2005).
241. Warner, P.L.J., Kornegay, G.B., Redl, G. Chlorhexidine salts and compositions of same. US4666896 (1987).
242. Friedman, J. Compositions for the sustained-release of chlorhexidine. US5002769 (1991).
243. Baker, J.R.J., Hamouda, T., Shih, A., Myc, A. Antimicrobial nanoemulsion compositions and methods. US7655252 (2010)
244. Schlag S, Nerz C, Birkenstock TA, Altenberend F, Gotz F. Inhibition of Staphylococcal biofilm formation by nitrite. J Bacteriol 2007; 189(21): 7911-9.
245. Summers WC. Bacteriophage therapy. Annu Rev Microbiol 2001; 55: 437-51.
246. Malik R, Chhibber S. Protection with bacteriophage KO1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. J Microbiol Immunol Infect 2009; 42(2): 134-40.
247. Soothill, J., Hawkins, C., Harper, D. Bacteriophage-containing therapeutic agents. US20070190033 (2007).
248. Walsh, S.M., Pittaway, M.C. Compositions and methods for treating bacteria. US7517852 (2009).
249. Wahdan HA. Causes of the antimicrobial activity of honey. Infection 1998; 26(1): 26-31.
250. [250] Subrahmanyam M. Topical application of honey in treatment of burns. Br J Surg 1991; 78(4): 497-8.
251. Mousa, M.A. Honey preparations. US5980875 (1999).
252. Mousa, M.A. Honey preparations. US6171604 (2001).
253. Van Den Berg, A.J., Hoekstra, M. Wound dressings incorporating honey. US20090304780 (2009).
254. Caskey, P.R. Honey in wound dressings. US20040127826 (2004).
255. Molan, P. Honey based wound dressing. US20040054313 (2004).
256. Holzner, G. Antimicrobial perfume compositions. US6479456 (2002).
257. Ang ES, Lee ST, Gan CS, See P, Chan YH, Ng LH, et al. The role of alternative therapy in the management of partial thickness burns of the face-experience with the use of moist exposed burn ointment (MEBO) compared with silver sulphadiazine. Ann Acad Med Singapore 2000; 29(1): 7-10.
258. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Can Microbiol 1969; 15(9): 1067-76.